11th World Affordable Medicine Congress

11th World Affordable Medicine Congress 7 - 8 February 2017, Barcelona, Spain.
The Annual World Affordable Medicine Congress comes to Barcelona, this is the newly rebranded World Generic Medicines Congress and Biosimilar Drug Development World. For 11 years, the biggest and best in the industry. Through a series of interactives presentation, speed networking and stream sessions, the congress will provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Don't miss out the opportunity to share your experience and network with senior and board level executives working in generic and biosimilar organisations.

Don't miss your chance to hear from:

  • Klaus Martin, Chief Scientific Officer, Polpharma Biologics
  • Matthew Turner, Global Medical Director Biosimilars, Merck
  • Bernd Liedert, Sr.Clinical Program Leader Biosimilars, Boehringer Ingelheim
  • Isabel Afonso, Head of Global Commercial Strategy and member of the Sandoz Executive Committee, Sandoz
  • Steinar Madsen, Medical Director, Norwegian Medicines Agency
  • Adrian Thomas, Vice President of Health Economics & Market Access, Janssen North America

Download the brochure now to see who's speaking.

World Pharma News readers can benefit from an exclusive 10% discount. Quote discount code CGNN

For further information, please visit:
http://www.healthnetworkcommunications.com/conference/affordable-medicines/

About World Affordable Medicine Congress
The World Affordable Medicine Congress Europe brings together two world class events - World Generic Medicines Congress and Biosimilar Drug Development World - that have been central to the industry’s business and networking needs for over 10 years. Over 2000 business leaders participants have benefited from this series since 2007.

The event unites senior executives from the generic and biosimilar industry to provide fresh insights into future market trends, innovative commercial strategies and opportunities for growth for affordable medicines.

Most Popular Now

New analysis shows Novartis Entresto improves glyc…

Novartis has announced results of a new post-hoc analysis in a subgroup of patients with reduced ejection fraction heart failure (HFrEF) and diabetes suggesting that Entr...

Read more

Mutual Recognition promises new framework for phar…

The United States and the European Union (EU) completed an exchange of letters to amend the Pharmaceutical Annex to the 1998 U.S.-EU Mutual Recognition Agreement. Under t...

Read more

Potential drug candidates halt prostate and breast…

Scientists on the Florida campus of The Scripps Research Institute (TSRI) have designed two new drug candidates to target prostate and triple negative breast cancers. The...

Read more

Novartis' Cosentyx shows almost all psoriasis pati…

Novartis has announced a new analysis showing that moderate-to-severe psoriasis patients treated with Cosentyx® (secukinumab) rapidly regain clear or almost clear skin (P...

Read more

Scientists stimulate immune system, stop cancer gr…

Researchers at the University of Illinois at Chicago report that increasing expression of a chemical cytokine called LIGHT in mice with colon cancer activated the immune ...

Read more

Johnson & Johnson completes acquisition of Abb…

Johnson & Johnson (NYSE: JNJ) has completed the acquisition of Abbott Medical Optics (AMO), a wholly-owned subsidiary of Abbott. The all-cash $4.325 billion acquisition w...

Read more

New England Journal of Medicine publishes long-ter…

In 2001 the U.S. Food and Drug Administration granted priority review for imatinib mesylate, sold under the name Gleevec®*, as an oral therapy for patients with chronic m...

Read more

Bristol-Myers Squibb expands focus on precision me…

Bristol-Myers Squibb Company (NYSE: BMY) announced its equity investment and plans for a research collaboration with GRAIL Inc., a life sciences company whose mission is ...

Read more

Volkswagen's excess emissions will lead to 1,200 p…

In September 2015, the German Volkswagen Group, the world's largest car producer, admitted to having installed "defeat devices" in 11 million diesel cars sold worldwide b...

Read more

MedImmune and Sanofi Pasteur form alliance to deve…

MedImmune, the global biologics research and development arm of AstraZeneca, and Sanofi Pasteur, the vaccines division of Sanofi, have announced an agreement to develop a...

Read more

Cooking at home tonight? It's likely cheaper and h…

Researchers from the University of Washington School of Public Health have been peeking into kitchens - via interviews - for years now. They've just published results sho...

Read more

Human antibody for Zika virus promising for treatm…

Researchers have determined the structure of a human antibody bound to the Zika virus, revealing details about how the antibody interferes with the infection mechanism - ...

Read more

Pharmaceutical Companies

[ A | B | C | D | E | F | G | H | I | J | K | L | M | N | O | P | Q | R | S | T | U | V | W | X | Z ]